Načítá se...
MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine
BACKGROUND: The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs’ immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as th...
Uloženo v:
| Vydáno v: | Neurol Sci |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8223191/ https://ncbi.nlm.nih.gov/pubmed/34165650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10072-021-05409-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|